SABCS 2021

A patient-level meta-analysis has demonstrated a significant reduction in the risk for invasive recurrence with the use of an anthracycline alongside taxane-based chemotherapy for the treatment of early-stage breast cancer.

Circulating tumor DNA target mutations may represent a promising prognostic biomarker among women receiving first-line ribociclib plus letrozole for hormone receptor-positive, HER2-negative advanced breast cancer, research suggests.

Dual checkpoint inhibition with nivolumab plus ipilimumab may be a promising treatment option for people with HER2-negative metastatic breast cancer and high tumor mutational burden, phase 2 NIMBUS study data show.